logo
portrait of smiling man stading in wooded areaportrait of smiling man stading in wooded areablue triangle graphic


Great Science
Deep Compassion
Real Impact

Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.

Discover Alkermes

Featured News

September 25, 2024

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Read more

September 23, 2024

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep E...

Read more

September 19, 2024

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.

Responsible Growth

Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.

View our latest report

Culture of Excellence



Our employees' dedication to patients and our communities is foundational to our culture. Hear how our team members contribute to building an organization dedicated to creating real impact.

Watch the video

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

Notable Recognition

We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes, based on the results of a third-party survey shared with our U.S.-based employees.

Visit our Awards & Recognition page

R&D Pipeline 


We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.

Click to view our interactive pipeline

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

  • Olanzapine and samidorphan

    • Schizophrenia and Bipolar I Disorder (Pediatric)

      Phase 3

    Overview

    Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.

    Clinical Trials

    Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.

  • ALKS 2680

    • Narcolepsy Type 1

      Phase 2

    • Narcolepsy Type 2

      Phase 2

    Overview

    ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.

    Clinical Trials

    ALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.

    For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:

  • Orexin Agonists

    • Neuroscience Indications

      Discovery

    Overview

    Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. 






Last updated: August 2024

Careers

  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.blue triangle graphic


Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We are driven to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.